Compounds > 1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2d)(1,2,3)-diazaborine
Page last updated: 2024-11-08

1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2d)(1,2,3)-diazaborine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2D)(1,2,3)-diazaborine: enoyl-ACP reductase inhibitor; synthetic antibacterial agent which inhibits lipopolysaccharide biosyn; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171833
CHEMBL ID174539
MeSH IDM0100783

Synonyms (14)

Synonym
6-methyl-2(propane-1-sulfonyl)-2h-thieno[3,2-d][1,2,3]diazaborinin-1-ol
diazaborine compound 2b18
DB08605
CHEMBL174539
1-hydroxy-6-methyl-2-propylsulfonylthieno[3,2-d]diazaborinine
sa-84474
1,2-dihydro-1-hydroxy-6-methyl-2-(propanesulfonyl)-thieno(3,2d)(1,2,3)-diazaborine
sa 84474
pkf 84.474
thieno(3,2-d)(1,2,3)diazaborine, 1,2-dihydro-1-hydroxy-6-methyl-2-(propylsulfonyl)-
67398-03-2
DTXSID00217752
Q27097804
PD004287
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID93882Minimum inhibitory concentration of compound against Klebsiella pneumoniae delta 2171984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID67858Minimum inhibitory concentration of compound against Enterobacter aerogenes delta 2201984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID200873Minimum inhibitory concentration of compound against Salmonella Typhimurium delta 1191984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID128843Antibacterial activity againist Escherichia coli 120 infected NMRI mice after peroral administration1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID147028Minimum inhibitory concentration of compound against Neisseria gonorrhoeae W21984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID147027Minimum inhibitory concentration of compound against Neisseria gonorrhoeae AS 77201984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID1850426Antibacterial activity against Salmonella typhimurium Delta-119 assessed as bacterial growth inhibition incubated for 16 hrs by broth dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Boron-Containing heterocycles as promising pharmacological agents.
AID69344Minimum inhibitory concentration of compound against Escherichia coli delta 1201984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
AID1850427Antibacterial activity against Klebsiella pneumoniae Delta-217 assessed as bacterial growth inhibition incubated for 16 hrs by broth dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Boron-Containing heterocycles as promising pharmacological agents.
AID162884Minimum inhibitory concentration against Proteus mirabilis delta 891984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (35.71)18.7374
1990's4 (28.57)18.2507
2000's2 (14.29)29.6817
2010's1 (7.14)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-keto-3-deoxyoctonate
[no description available]		1.9610
nalidixic acid
[no description available]		1.98101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
triclosan
[no description available]		210aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
globomycin
[no description available]		1.9810cyclodepsipeptide
palmitoleic acid
hexadecenoate : A long-chain unsaturated fatty acid anion that is the conjugate base of hexadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		1.9810hexadec-9-enoic acidalgal metabolite;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
human blood serum metabolite
palmitoyl coenzyme a
Palmitoyl Coenzyme A: A fatty acid coenzyme derivative which plays a key role in fatty acid oxidation and biosynthesis.. palmitoyl-CoA : A long-chain fatty acyl-CoA resulting from the formal condensation of the carboxy group of hexadecanoic acid with the thiol group of coenzyme A.		1.991011,12-saturated fatty acyl-CoA;
3-substituted propionyl-CoA;
long-chain fatty acyl-CoA;
palmitoyl bioconjugate		Escherichia coli metabolite;
mouse metabolite
nadp
[no description available]		1.9910
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		1.9810
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		1.9810epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
cis-vaccenic acid
cis-vaccenic acid: isomer of oleic acid. vaccenic acid : An octadecenoic acid having a double bond at position 11; and which can occur in cis- or trans- configurations.. cis-vaccenic acid : The cis isomer of vaccenic acid.		1.9810vaccenic acid
talabostat
talabostat: an antineoplastic agent; structure in first source		3.5110
dutogliptin
[no description available]		3.5110
tavaborole
tavaborole: has antifungal activity; structure in first source. tavaborole : A member of the class of benzoxaboroles that is 1,3-dihydro-1-hydroxy-2,1-benzoxaborole substituted at position 5 by a fluoro group. A topical antifungal agent used for the treatment of onychomycosis (fungal infection of the toenails and fingernails).		3.5110benzoxaborole;
organofluorine compound		antifungal agent;
EC 6.1.1.4 (leucine--tRNA ligase) inhibitor;
protein synthesis inhibitor
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9910organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
scyx 7158
[no description available]		3.5110(trifluoromethyl)benzenes
ConditionIndicatedRelationship StrengthStudiesTrials